Hungary’s pharmaceutical industry is a key pillar of the national economy and global competitiveness. believes Foreign Minister Péter Szijjártó. Continue reading
Gedeon Richter Nyrt. reported first-half results in line with its annual targets, prompting the company to maintain its 2025 growth forecast, CEO Gábor Orbán announced on Wednesday in Budapest.
Adjusting for currency fluctuations, the pharmaceutical giant anticipates approximately 10% growth in both revenue and adjusted EBIT for the year. Pharmaceutical manufacturing, which accounts for 98% of sales, rose 11% in the second quarter to 237.5 billion HUF (cc. 598 million EUR/1 EUR = 397 HUF), bringing half-year revenue to 458 billion HUF.
The gynecology division accelerated notably with 19% growth in Q2, fueled by strong demand across Western and Eastern Europe. Key therapeutic areas—including infertility, menopause, and endometriosis treatments—achieved double-digit gains, while contraceptive sales also outperformed last year’s figures.
Meanwhile, the generics segment expanded 7.7% to surpass 130 billion HUF, despite a slowdown in volume growth during the quarter.
Gábor Orbán, Gedeon Richter’s CEO; Photo: Hungary Today
Research and development expenditures rose 8%, accounting for 11% of revenue. CFO László Kovács highlighted that currency headwinds weighed on net profit, which stood at 120 billion HUF for the first half—a 13% decline compared to 2024.
Orbán addressed the ongoing uncertainty surrounding U.S. tariff policies and underscored challenges to European pharmaceutical competitiveness, exacerbated by the global minimum tax.
He also expressed concern over a state-supported rival’s investment in Gödöllő, which aims to recruit biotech specialists currently employed by Richter.
While no new acquisitions are planned this year, the company remains vigilant in assessing potential opportunities. Richter shares are traded on the Budapest Stock Exchange’s premium segment, with prices fluctuating between 9,500 HUF and 11,260 HUF over the past year.
Via MTI; Featured image: Facebook/Richter Gedeon Nyrt.